SSR-180,711

SSR-180,711
(IUPAC) ime
	(4-bromofenil) 1,4-diazabiciklo[3.2.2]nonan-4-karboksilat
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	9928899
Hemijski podaci
Formula	C14H21BrN2O2
Mol. masa	329,232
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C14H17BrN2O2/c15-11-1-3-13(4-2-11)19-14(18)17-10-9-16-7-5-12(17)6-8-16/h1-4,12H,5-10H2 ; Key: RXLOZRCLQMJJLC-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

SSR-180,711 je lek koji deluje kao potentan i selektivan parcijalni agonist za α7 tip neuronskog nikotinskog acetilholinskog receptora.^[3]^[4] U životinjskim studijama on je pokazao nutropne efekte, te potencijalno može da bude koristan u tretmanju šizofrenije.^[5]^[6]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Pichat, P.; Bergis, O.; Terranova, J.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C. i dr.. (2007). „SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia”. Neuropsychopharmacology 32 (1): 17–34. DOI:10.1038/sj.npp.1301188. PMID 16936709.
↑ Biton, B.; Bergis, O.; Galli, F.; Nedelec, A.; Lochead, A.; Jegham, S.; Godet, D.; Lanneau, C. i dr.. (2007). „SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile”. Neuropsychopharmacology 32 (1): 1–16. DOI:10.1038/sj.npp.1301189. PMID 17019409.
↑ Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. (2008). „Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711”. Biological Psychiatry 63 (1): 92–97. DOI:10.1016/j.biopsych.2007.04.034. PMID 17601496.
↑ Barak, S.; Arad, M.; De Levie, A.; Black, M.; Griebel, G.; Weiner, I. (2009). „Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia”. Neuropsychopharmacology 34 (7): 1753–1763. DOI:10.1038/npp.2008.232. PMID 19158670.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Pichat, P.; Bergis, O.; Terranova, J.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C. i dr.. (2007). „SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia”. Neuropsychopharmacology 32 (1): 17–34. DOI:10.1038/sj.npp.1301188. PMID 16936709.

[4] Biton, B.; Bergis, O.; Galli, F.; Nedelec, A.; Lochead, A.; Jegham, S.; Godet, D.; Lanneau, C. i dr.. (2007). „SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile”. Neuropsychopharmacology 32 (1): 1–16. DOI:10.1038/sj.npp.1301189. PMID 17019409.

[5] Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. (2008). „Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711”. Biological Psychiatry 63 (1): 92–97. DOI:10.1016/j.biopsych.2007.04.034. PMID 17601496.

[6] Barak, S.; Arad, M.; De Levie, A.; Black, M.; Griebel, G.; Weiner, I. (2009). „Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia”. Neuropsychopharmacology 34 (7): 1753–1763. DOI:10.1038/npp.2008.232. PMID 19158670.

[1]

[2]

[3]

[4]

[5]

[6]